|
1
|
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
|
Lancet Oncol
|
2010
|
4.10
|
|
2
|
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
|
Blood
|
2011
|
2.58
|
|
3
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
|
Blood
|
2006
|
2.51
|
|
4
|
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
|
J Clin Oncol
|
2008
|
2.09
|
|
5
|
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
|
Haematologica
|
2002
|
2.08
|
|
6
|
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
|
Blood
|
2005
|
1.97
|
|
7
|
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma.
|
Blood
|
2006
|
1.57
|
|
8
|
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
|
Haematologica
|
2005
|
1.56
|
|
9
|
Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
|
J Clin Oncol
|
2004
|
1.50
|
|
10
|
[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].
|
Med Clin (Barc)
|
2009
|
1.40
|
|
11
|
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
|
Biol Blood Marrow Transplant
|
2007
|
1.06
|
|
12
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
|
Haematologica
|
2008
|
1.06
|
|
13
|
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
|
Haematologica
|
2010
|
0.90
|
|
14
|
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
|
Haematologica
|
2006
|
0.84
|
|
15
|
Expression of heat shock proteins in classical Hodgkin lymphoma: correlation with apoptotic pathways and prognostic significance.
|
Histopathology
|
2011
|
0.80
|
|
16
|
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
|
Clin Cancer Res
|
2004
|
0.80
|